Biotech Stock Still 700%: What Investors Should Do Today
A biotech stock still 700% has defied gravity, even as it slumps 30% this year. Learn how to read the signals, what a...
A side-by-side look at Sp 500 Equity and Multi Asset Retirement allocations, examining growth potential, risk, and diversification for retirement planning.
27,235 articlesA biotech stock still 700% has defied gravity, even as it slumps 30% this year. Learn how to read the signals, what a...
Two dividend ETFs quietly beating SCHD on total return since early 2022 have captured investor interest as market con...
Global equities outside the US have surged as growth improves and the dollar weakens. This article highlights three E...
In the first five months of 2026, luxury buyer interest doubles in the U.S. luxury market, with buyers favoring large...
Bitcoin sits in a delicate consolidation phase as traders grapple with potentially game-changing levels. On-chain dat...
Ken Griffin, the Citadel founder once openly skeptical of AI, has pivoted to embracing its potential, telling audienc...
Two of Washington’s most watched political figures disclosed stakes in Vistra, a mid-size energy player poised as AI ...
During 13F season, big investors reveal shifts in their portfolios. This piece explains the move, why Microsoft was f...
Investors are weighing Microsoft’s next steps in a fast-changing tech landscape. This guide breaks down likely cataly...
A prominent investor dumped a multi‑million stake in a biotech stock that’s up double digits. This article explains w...
A niche nuclear tech stock reported solid revenue gains, but a large fund reduced its holdings. Learn how to read the...
A sharp 60% drop in CBIZ shares has investors buzzing about risk and value. This guide breaks down why the stock move...